Literature DB >> 33990479

Transcatheter mitral valve replacement: an update.

Joe Aoun1, Michael J Reardon2, Sachin S Goel1.   

Abstract

PURPOSE OF REVIEW: A significant number of patients with mitral valve disease are at high to prohibitive risk for surgical repair or replacement. Transcatheter mitral valve interventions have evolved over the last few years. We review the recent growing evidence on transcatheter mitral valve replacement (TMVR). RECENT
FINDINGS: Tendyne is the first TMVR device commercially approved in Europe. All TMVR systems remain under investigation in the United States. Several early studies have reported the feasibility and safety outcomes for TMVR implanted via transapical or transseptal approach. TMVR using balloon expandable valve for degenerated bioprosthetic valves, surgical rings and mitral annular calcification appears feasible in selected patients.
SUMMARY: Early experience with TMVR systems is promising. Larger ongoing studies will help understand longer term outcomes and offer insights into patient selection.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33990479     DOI: 10.1097/HCO.0000000000000884

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  1 in total

1.  In-hospital outcomes of patients undergoing concomitant aortic and mitral valve replacement in Germany.

Authors:  Maximilian Kreibich; Klaus Kaier; Constantin von Zur Mühlen; Matthias Siepe; Manfred Zehender; Christoph Bode; Friedhelm Beyersdorf; Peter Stachon; Wolfgang Bothe
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.